A live dengue virus vaccine carrying a chimeric envelope glycoprotein elicits dual DENV2-DENV4 serotype-specific immunity

Ellen Young, Boyd Yount, Petraleigh Pantoja, Sandra Henein, Rita M. Meganck, Jennifer McBride, Jennifer E. Munt, Thomas J. Baric, Deanna Zhu, Trevor Scobey, Stephanie Dong, Longping V. Tse, Melween I. Martinez, Armando G. Burgos, Rachel L. Graham, Laura White, Aravinda DeSilva, Carlos A. Sariol and Ralph S. Baric ()
Additional contact information
Ellen Young: University of North Carolina
Boyd Yount: University of North Carolina
Petraleigh Pantoja: University of Puerto Rico-Medical Sciences Campus
Sandra Henein: University of North Carolina
Rita M. Meganck: Saint Louis University
Jennifer McBride: University of North Carolina
Jennifer E. Munt: University of North Carolina
Thomas J. Baric: University of North Carolina
Deanna Zhu: University of North Carolina
Trevor Scobey: University of North Carolina
Stephanie Dong: University of North Carolina
Longping V. Tse: Saint Louis University
Melween I. Martinez: University of Puerto Rico-Medical Sciences Campus
Armando G. Burgos: University of Puerto Rico-Medical Sciences Campus
Rachel L. Graham: University of North Carolina
Laura White: University of North Carolina
Aravinda DeSilva: University of North Carolina
Carlos A. Sariol: University of Puerto Rico-Medical Sciences Campus
Ralph S. Baric: University of North Carolina

Nature Communications, 2023, vol. 14, issue 1, 1-12

Abstract: Abstract The four dengue virus serotypes co-circulate globally and cause significant human disease. Dengue vaccine development is challenging because some virus-specific antibodies are protective, while others are implicated in enhanced viral replication and more severe disease. Current dengue tetravalent vaccines contain four live attenuated serotypes formulated to theoretically induce balanced protective immunity. Among the number of vaccine candidates in clinical trials, only Dengvaxia is licensed for use in DENV seropositive individuals. To simplify live-virus vaccine design, we identify co-evolutionary constraints inherent in flavivirus virion assembly and design chimeric viruses to replace domain II (EDII) of the DENV2 envelope (E) glycoprotein with EDII from DENV4. The chimeric DENV2/4EDII virus replicates efficiently in vitro and in vivo. In male macaques, a single inoculation of DENV2/4EDII induces type-specific neutralizing antibodies to both DENV2 and DENV4, thereby providing a strategy to simplify DENV vaccine design by utilizing a single bivalent E glycoprotein immunogen for two DENV serotypes.

Date: 2023
References: View references in EconPapers View complete reference list from CitEc
Citations:

Downloads: (external link)
https://www.nature.com/articles/s41467-023-36702-x Abstract (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:natcom:v:14:y:2023:i:1:d:10.1038_s41467-023-36702-x

Ordering information: This journal article can be ordered from
https://www.nature.com/ncomms/

DOI: 10.1038/s41467-023-36702-x

Access Statistics for this article

Nature Communications is currently edited by Nathalie Le Bot, Enda Bergin and Fiona Gillespie

More articles in Nature Communications from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().